Compare BSVN & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSVN | NGNE |
|---|---|---|
| Founded | 2004 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 416.1M | 744.9M |
| IPO Year | 2018 | 2014 |
| Metric | BSVN | NGNE |
|---|---|---|
| Price | $49.53 | $34.41 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 7 |
| Target Price | $53.67 | ★ $63.57 |
| AVG Volume (30 Days) | 30.0K | ★ 310.4K |
| Earning Date | 04-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ 0.93 |
| EPS | ★ 1.25 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.05 | N/A |
| Revenue Next Year | $4.05 | N/A |
| P/E Ratio | $40.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $38.50 | $15.93 |
| 52 Week High | $53.00 | $43.66 |
| Indicator | BSVN | NGNE |
|---|---|---|
| Relative Strength Index (RSI) | 52.30 | 47.61 |
| Support Level | $40.17 | $18.24 |
| Resistance Level | $53.00 | $37.27 |
| Average True Range (ATR) | 1.56 | 3.04 |
| MACD | -0.34 | -0.65 |
| Stochastic Oscillator | 36.94 | 17.67 |
Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.